HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Debuts List For Rapidly Announcing Noncompliant Ingredients In Supplements

Executive Summary

FDA announces addition of Dietary Supplement Ingredient Advisory List page to its website to identify ingredients it has preliminary determined should be used in dietary supplements. It also publishes warning letters submitted recently to firms marketing supplements containing two ingredients agency has concluded should not be used: eight were warned about using an ingredient identified as "DMHA" and three about using phenibut.

You may also be interested in...



US FDA Warns About Botanicals Determined As Unlawful Being Used As Dietary Ingredients

One or more of 5-alpha-hydroxy laxogenin, higenamine, hordenine and octopamine is used by 11 firms FDA warned in products labeled as supplements and marketed as beneficial for weight loss and strength training.

FDA's Latest Hornedine Find Is On Texas Firm’s Supplement Labels During Website Inspection

Hornedine isn’t an “old” dietary ingredient exempt from pre-market notification with proof its safety because it wasn’t available in the US food supply before October 1994. "T

US Supplement Firm Warned About Phenibut After Failing To Pull PTSD, Detox, Anxiety Claims

Latest FDA warning to Chill6 doesn’t reference previous letter but lists larger number of violations along with more details about the problems. Agency also recently added salt scrub therapies to its list of products as marketed with fraudulent coronavirus treatment claims.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS148731

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel